AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04732156 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: Measurement of PHI Index
Study NCT04732156 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Follow up questionnaire
Description: 3 years after inclusion
Study NCT04732156 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Human reading of prostate MR images (PI-RADSv2.1).
Description: The PI-RADSv2.1 score will be compared to systematic and targeted biopsy findings (primary objective) and 3-year follow-up (secondary objective)
Study NCT05597605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The SHINE SYSTEM
Description: The FUSHO sensor, which is part of the SHINE SYSTEM, is a continuous multi-metabolite monitoring (CMM) sensor which is a miniaturized near-infrared spectrometer that measures the absorption of light in the interstitial fluid to quantify the concentration of multiple metabolites
Study NCT06496100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triticum Aestivum
Description: The intervention period will be 120 days, looking for effects on appetite regulation and the hormonal axis Leptin, Ghrelin and Adiponectin.
Study NCT06496100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (calcined magnesia)
Description: The intervention period will be 120 days, looking for effects on appetite regulation and the hormonal axis Leptin, Ghrelin and Adiponectin.
Study NCT06136299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Training
Description: This intervention uses the FIFA 11+ Kids program as a warm-up during soccer practice sessions.
Study NCT05581875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin-Blmf
Description: Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder. Blmf will be delivered as IV solution over at least 30 minutes
Study NCT05581875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.
Study NCT05581875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered per os.
Study NCT05581875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered intravenously or per os.
Study NCT05641675 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: right heart catheterization
Description: Connect to a heart monitor to record heart rate, blood pressure and blood oxygen levels Place sterile sheets on chest and neck (or groin area) Clean the skin over the neck or groin Give local anaesthetic to numb the area (this may sting a little when it is given) Gently pass a catheter into a vein to the heart Record pressure readings from the heart chambers and lungs Give medication, depending on heart's pressure readings Remove the catheter and apply pressure where it was inserted
Study NCT04235803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up
Description: A telemedicine follow-up form based in REDCap that collects information from the patient including: history, photographs, vision measurement, and questions.
Study NCT05927324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAVEAT
Description: Brief psychotherapy with mothers of infants and young children, to which infants and young children attend many but not all sessions with mother
Study NCT06508749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS
Description: IV Antibody Infusion based on subject's weight
Study NCT06508749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: IV Antibody Infusion based on subject's weight
Study NCT06508749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS
Description: IV Antibody Infusion based on subject's weight
Study NCT06508749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART Regimen prior to enrolling in Step 1a
Description: Antiviral drugs are not study product. However, participants will continue to receive the ART regimen they were receiving prior to enrolling in the study during Step 1a.
Study NCT06508749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART Regimen prior to enrolling in Step 1b
Description: Antiviral drugs are not study product. However, participants will continue to receive the ART regimen they were receiving prior to enrolling in the study during Step 1b.
Study NCT06508749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analytic Treatment Interruption
Description: (all anti-HIV agents are discontinued)
Study NCT05623007 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counselling on healthy eating, physical activity, and psychosocial stimulation
Description: Counselling on healthy eating, physical activity, and psychosocial stimulation.
Study NCT05623007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling on healthy eating, physical activity, and psychosocial stimulation
Description: Counselling on healthy eating, physical activity, and psychosocial stimulation.
Study NCT06529133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of postural control
Description: Postural stability, limits of stability, and modified clinical test of sensory interaction in balance tests will be performed with Biodex Balance System (BBS). 1) Postural Stability: The test will be performed on a stable platform and mean, anterior/posterior and medial/lateral stability indices will be calculated. 2) Limits of Stability: The test will be performed on a static platform and directional control will be evaluated and expressed as a percentage value. 3) Modified Clinical Test of Sensory Interaction in Balance: The test will be performed with a static platform setting on a flat surface with eyes open and eyes closed, on a foam floor with eyes open and eyes closed. Half an hour later, the same tests will be repeated during the cognitive dual task. The cognitive tasks given were counting day-month-season, rhythmic forward and backward counting (counting by 2, 3, 5, 10, etc.), counting words related to a given letter (animal names starting with the letter A, city names, etc.).
Study NCT06332092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FID007
Description: Patients will receive FID007 via IV infusion at their assigned dose on Days 1, 8, and 15 of each 28-day cycle. Starting from Cycle 2, Cetuximab will be administered every 2 weeks on Days 1 and 15 of each 28-day cycle.
Study NCT06461442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Extremely cold liquid (liquid nitrogen) will used by a dermatologist to freeze and destroy abnormal cells in the treatment areas randomized to this treatment.
Study NCT06461442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: Patients will apply 5% 5-Fluorouracil cream in a thin layer twice daily for 4 weeks on the treatment areas randomized to this treatment.
Study NCT04914546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3819469
Description: Administered SC.
Study NCT04914546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT05407064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-120 (LSD D-Tartrate)
Description: A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
Study NCT05407064 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance that is designed to have no therapeutic value.
Study NCT05623007 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo probiotics
Description: Maltodextrin
Study NCT06001268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit Data Collection
Description: Participants will log food intake while sharing their data with a dietician in real time for 12 weeks
Study NCT05958875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Participants are randomized to clozapine or second-line antipsychotics. When randomised to clozapine, they will receive clozapine for six weeks.
Study NCT05958875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Second-line Antipsychotics (treatment as usual)
Description: Participants are randomized to clozapine or second-line antipsychotics. When randomized to second-line antipsychotics, this means participants will receive treatment as usual. The physician has the choice to administer any second-line antipsychotic. More specification is not possible, as this is a choice the physician makes with the participant based on the characteristic and preference of the participant (in line with standard clinical practice).
Study NCT02903212 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous apoptotic cells injection
Description: cells injection
Study NCT05031598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-term fasting according to the Buchinger Wilhelmi fasting program
Description: the participants will undergo a fasting program that includes the daily intake of 250 kcal under medical supervision
Study NCT04777838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram 10 MG
Description: 10 mg of citalopram every day
Study NCT04777838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 25mg of Amitriptyline every
Study NCT06646926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body tempering
Description: Participant will be positioned prone on the Body Tempering Ab Mat with their feet hanging off the end of the mat. The body tempering intervention will be applied by the same investigator for all trials. The body tempering device will be applied dynamically to each participant for 4 minutes, with the device placed on both participants' lower extremities at the same time. First, the examiner will set a timer for two minutes and begin rolling one 80-pound body tempering device along the participant's gastrocnemius-soleus complex at a rate of 30 beats per minute, traveling from the Achilles tendon (medial malleolus) to the inferior aspect of the popliteal fossa, indicated by fibular head. The participant will then take thirty seconds to transition to a supine position and receive tempering with an 80-pound tempering device along their middle to distal quadriceps, set a timer for 2 minutes.
Study NCT06646926 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foam rolling self-myofascial release
Description: Participants will be instructed via standardized script to perform self-myofascial release (SMR) on their gastrocnemius-soleus complex and quadriceps muscles. The first SMR sequence will be performed by having the participant place the foam roller behind both calves, beginning the roll at the medial malleolus and ending at the inferior aspect of the popliteal fossa, indicated by the fibular head. The participant will perform this for two minutes, rolling at a tempo of 30 beats per minute. Next, the participant will take thirty seconds to transition to a prone position, placing the foam roller just distal to the hip crease, just inferior to the AIIS, and rolling inferiorly to the area just proximal to the most superior aspect of the patella. This self-release sequence will be performed for two minutes at a tempo of 30 beats per minute. The total time should be four minutes, matching the total time of the experimental intervention group.
Study NCT05587712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: SC injection every 3 weeks (Q3W) of 0.3 mg/kg. Dosage may be adjusted based on protocol-specific guidelines.
Study NCT05692115 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: stress ECG
Description: stress ECG to patients suspected to be ischemic patients .
Study NCT05569005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THS use
Description: Subjects who are not willing to quit smoking during the study duration will switch from cigarettes to using THS
Study NCT05569005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette
Description: Subjects who are not willing to quit smoking during the study duration will continue smoking their own preferred brand of commercially available cigarettes.
Study NCT05569005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Abstinence
Description: Subjects who are willing to quit smoking may be prescribed an NRT to support them in remaining abstinent from use of any tobacco and nicotine containing products during the study. (Behavioral support will be provided to subjects to aid with abstinence.)
Study NCT06001268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Counseling
Description: Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth or in person.
Study NCT06001268 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Counseling
Description: Participants will receive individually tailored, bi-weekly nutrition counseling from a dietician via telehealth or in person.
Study NCT06001268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Participants will take a survey at baseline and weeks 4,8,\& 12. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
Study NCT06001268 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: Participants will take a survey at baseline and weeks 4,8,\& 12. (FACT-G) Questionnaire includes questions about participant's physical, social, emotional and functional well being over the past 7 days. This questionnaire uses a 5 point Likert-type scale, 0=not at all, 4=very much. A higher total score indicates better quality of life.
Study NCT05543915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: The tDCS-MRI scan will last approximately one hour. The first 20 minutes of the MRI will not include tDCS stimulation. After 20 minutes, the tDCS device will ramp up to 2.0mA and deliver 2.0mA for 20 minutes. Then the tDCS will ramp down (30 seconds) and the final 20 minutes will be without stimulation.
Study NCT05011266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: 5.7 mg buprenorphine/1.4 mg naloxone sub-lingual daily
Study NCT05011266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo sub-lingual tablet daily
Study NCT04777838 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bite Splint
Description: Night use of occlusal splint
Study NCT06023524 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture and Standard Medication
Description: Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. Dose 4 Joule at the acupuncture body points and 1 Joule at the ear points
Study NCT06023524 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser Acupuncture and Standard Medication
Description: Laser Acupuncture: using RJ laser Nogier E program, with 4672Hz, 785 nm and power 70 mW. The laser is turned on but not activated
Study NCT04702854 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Biomicroscopy
Description: Measure of cutaneous melanomas by ultrasound Biomicroscopy
Study NCT06169631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gen0b
Description: The ultrasound will be administered to the brain region of interest.
Study NCT06518902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells (umbilical cord) injection
Description: Patients receive mesenchymal stem cells (umbilical cord) injection once or once a week for three consecutive weeks
Study NCT05799183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Subjects will receive treatment SHR-1210 before process changes 20 mg
Study NCT05799183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Subjects will receive treatment SHR-1210 after process changes 20 mg
Study NCT03942211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 (200 µg) to 8 (1600 µg) tablets at each administration
Study NCT03942211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets without active compound. Participants can receive 1 to 8 tablets at each administration.
Study NCT05499728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation; physical therapy via telecommunication device (i.e. online video conferencing)
Description: Postoperative physical therapy performed through online video conferencing with a licensed physical therapist while the patient remains remote/at home rather than in person
Study NCT04817995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOREST
Description: Intervention is going to take the form of an internet-based stress recovery intervention consisting of six modules. The themes include introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. These themes were chosen after considering topics that might be the most useful for healthcare staff experiencing high levels of stress. Each module consists of psychoeducation and exercise parts. Psychologist provide individual feedback on completed exercises as well as can be reached on demand.
Study NCT05736913 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ID BNT162b2 vaccine
Description: intradermal BNT162b2 vaccine
Study NCT05736913 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IM BNT162b2 vaccine
Description: intramuscular BNT162b2 vaccine
Study NCT06467058 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DABQ questionnaire versus Actigraph as reference method
Description: In this study, participants will have one contact session with the researcher, which will be held either at Ghent University Hospital or at the participants' home. During this session, participants will be provided with an accelerometer device and two questionnaires (to be filled in after wearing the Actigraph), namely the Daily Activity Behavior Questionnaire (DABQ) and general information questionnaire.~The participants will receive an Actigraph wGT3X+BT accelerometer which will be worn for seven consecutive days. Instructions will be given on how to wear the accelerometer (e.g. during the day at the hip and during the night at the wrist). At the end of this week, the participants will fill in both questionnaires. After wearing the accelerometer for seven consecutive days and filling in both questionnaires, the researcher will visit the participants to collect the devices, or the participants will send them back by postal package.
Study NCT04974580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: NRT will be discussed and dosed by the study quit coach during coaching calls per quitline dosing protocols. NRT treatment will consist of up to an 8 week supply of nicotine patch, gum, and/or lozenge. NRT will be sent in two 4 week shipments. Participants may be dosed for a single form of NRT or combination NRT (patch plus gum or lozenge) based on coach assessment of nicotine use and participant preference.
Study NCT04974580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Counseling
Description: Participants in all four arms of the study will receive two proactive phone-based behavioral coaching calls for quitting vaping, which will include making a quit plan, learning to cope with urges to vape, and education on strategies for quitting and staying quit. Calls utilize the quitline evidence-based protocol. The first call lasts approximately 20 minutes, the second calls lasts approximately 10 minutes, and participants are encouraged to call in for ad hoc calls if they would like additional support.
Study NCT04974580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Coaching
Description: Intervention descriptionText-based vaping cessation program that utilizes evidence-based content from the quitline tobacco cessation protocol, as well as links directing participants to additional online educational content (brief videos, audio content, quizzes, and educational activities).
Study NCT05122143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Nasal Spray with drug-free aqueous gel emulsion (AM-301) intended to help protect against airborne allergens.~One Spray of AM-301 per nostril
Study NCT04707716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conometric concept Acuris system
Description: implant crown retention type using friction only
Study NCT05456438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: İntervention 1
Description: Group 1 applied coconut oil to the nipple
Study NCT04707716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: screw retention
Description: screw retained implant crown
Study NCT05456438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: İntervention 2
Description: Group 2 applied tea tree oil to the nipple
Study NCT05223335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75 mg/day
Study NCT05223335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: 60 mg bolus then 10 mg daily